Standard immunosuppression in IBD: current practice.
Feagan
B G
BG
London Health Science Centre, University of Western Ontario, London, Ontario, Canada.
D000963:Antimetabolites / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000276:immunology; D008727:Methotrexate / Q000627:therapeutic use
D000963:Antimetabolites; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine; D008727:Methotrexate